$TEVA insider trading
Over the last 12 months, Teva Pharmaceutical Industries insiders reported no purchases and 42 sales totaling $91.7M across SEC Form 4 filings. 52% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $91.7M 42 events
- Events · 12m
- 42 Form 4 filings, grouped
- Insiders · 12m
- 14 distinct reporters
- 10b5-1 share
- 52% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Weiss AmirChief Accounting Officer · O | ▼ Sale | 9,445 | $37.62 | $355K | -41.9% | 2 tranches |
| Aug 21, 2026 | Satchi-Fainaro RonitD | ▼ Sale | 415 | $37.25 | $15K | -0.4% | — |
| Aug 17, 2026 | Lippman EvanEVP, Business Development · O | ▼ Sale | 18,600 | $36.57 | $680K | -42.1% | plan |
| Aug 5, 2026 | Zaks Tal ZviD | ▼ Sale | 17 | $34.87 | $593 | — | — |
| Aug 3, 2026 | Jover PlacidSee "Remarks" · O | ▼ Sale | 12,827 | $34.88 | $447K | -65.4% | plan |
| Aug 3, 2026 | Hughes Eric ASee "Remarks" · O | ▼ Sale | 25,578 | $34.88 | $892K | -15.9% | plan |
| Jun 18, 2026 | Shields MatthewEVP, Global Operations · O | ▼ Sale | 9,989 | $32.19 | $322K | -100% | — |
| Jun 11, 2026 | Kalif Eliyahu SharonEVP, Chief Financial Officer · O | ▼ Sale | 106,563 | $34.1 | $3.6M | -61.9% | plan |
| Jun 5, 2026 | Francis Richard DPresident and CEO · O | ▼ Sale | 6,153 | $34.35 | $211K | -0.5% | plan |
| Jun 3, 2026 | Shields MatthewEVP, Global Operations · O | ▼ Sale | 16,195 | $32.87 | $532K | -61.9% | plan |
| May 6, 2026 | Weiss AmirChief Accounting Officer · O | ▼ Sale | 10,679 | $36 | $384K | -34.8% | — |
| May 5, 2026 | Daniell RichardEVP, Europe Commercial · O | ▼ Sale | 30,000 | $35.4 | $1.1M | -35% | — |
| May 1, 2026 | Sabag MarkSee "Remarks" · O | ▼ Sale | 144,180 | $34.99 | $5.0M | -64.1% | — |
| Apr 30, 2026 | Fox ChristineEVP, U.S. Commercial · O | ▼ Sale | 21,258 | $35.31 | $751K | -25% | — |
| Mar 17, 2026 | Sabag MarkSee "Remarks" · O | ▼ Sale | 62,102 | $30.14 | $1.9M | -21.6% | — |
| Mar 5, 2026 | Francis Richard DPresident and CEO · O | ▼ Sale | 20,025 | $31.67 | $634K | -1.7% | plan |
| Mar 5, 2026 | Fox ChristineEVP, U.S. Commercial · O | ▼ Sale | 7,924 | $31.67 | $251K | -8.5% | plan |
| Mar 5, 2026 | Hughes Eric ASee "Remarks" · O | ▼ Sale | 9,533 | $31.67 | $302K | -8.1% | plan |
| Mar 5, 2026 | Daniell RichardEVP, Europe Commercial · O | ▼ Sale | 17,295 | $31.67 | $548K | -16.8% | plan |
| Mar 5, 2026 | Jover PlacidSee "Remarks" · O | ▼ Sale | 14,150 | $31.67 | $448K | -67.6% | plan |
| Mar 5, 2026 | Savage BrianInterim Chief Legal Officer · O | ▼ Sale | 1,127 | $31.67 | $36K | -9.4% | — |
| Mar 5, 2026 | Shields MatthewEVP, Global Operations · O | ▼ Sale | 17,295 | $31.67 | $548K | -63.4% | plan |
| Mar 4, 2026 | Francis Richard DPresident and CEO · O | ▼ Sale | 23,393 | $32.46 | $759K | -2% | plan |
| Mar 4, 2026 | Daniell RichardEVP, Europe Commercial · O | ▼ Sale | 91,345 | $32.66 | $3.0M | -51.6% | plan · 3 tranches |
| Mar 4, 2026 | Hughes Eric ASee "Remarks" · O | ▼ Sale | 11,277 | $32.46 | $366K | -10.4% | plan |
| Mar 4, 2026 | Fox ChristineEVP, U.S. Commercial · O | ▼ Sale | 9,098 | $32.46 | $295K | -10.8% | plan |
| Mar 4, 2026 | Savage BrianInterim Chief Legal Officer · O | ▼ Sale | 2,675 | $32.46 | $87K | -24% | 2 tranches |
| Mar 3, 2026 | Daniell RichardEVP, Europe Commercial · O | ▼ Sale | 128,985 | $32.36 | $4.2M | -51.2% | plan · 2 tranches |
| Mar 3, 2026 | Savage BrianInterim Chief Legal Officer · O | ▼ Sale | 1,274 | $32.36 | $41K | -30.3% | — |
| Mar 3, 2026 | Francis Richard DPresident and CEO · O | ▼ Sale | 442,935 | $32.36 | $14.3M | -28.3% | plan · 2 tranches |
| Mar 3, 2026 | Hughes Eric ASee "Remarks" · O | ▼ Sale | 80,762 | $32.36 | $2.6M | -48.5% | plan · 2 tranches |
| Feb 26, 2026 | Kalif Eliyahu SharonEVP, Chief Financial Officer · O | ▼ Sale | 345,810 | $33.64 | $11.6M | -85.7% | plan |
| Feb 15, 2026 | Francis Richard DPresident and CEO · O | ▼ Sale | 447,778 | $34.22 | $15.3M | -42.5% | plan · 2 tranches |
| Dec 16, 2025 | Weiss AmirChief Accounting Officer · O | ▼ Sale | 12,300 | $30.2 | $372K | -68.5% | — |
| Dec 16, 2025 | MIGNONE ROBERTOD | ▼ Sale | 77,400 | $30.24 | $2.3M | -17.4% | indirect |
| Dec 9, 2025 | Daniell RichardExec. VP, European Commercial · O | ▼ Sale | 115,468 | $28.68 | $3.3M | -70.5% | — |
| Dec 9, 2025 | Sabag MarkSee "Remarks" · O | ▼ Sale | 216,892 | $28.73 | $6.2M | -80.4% | 2 tranches |
| Nov 26, 2025 | MIGNONE ROBERTOD | ▼ Sale | 50,000 | $26.03 | $1.3M | -10.1% | indirect |
| Nov 20, 2025 | Fox ChristineEVP, Head of U.S. Commercial · O | ▼ Sale | 28,229 | $24.78 | $700K | -30.7% | plan |
| Nov 14, 2025 | Fox ChristineEVP, Head of U.S. Commercial · O | ▼ Sale | 30,000 | $25.11 | $753K | -51.4% | — |
| Nov 6, 2025 | MIGNONE ROBERTOD | ▼ Sale | 200,000 | $24.11 | $4.8M | -28.8% | indirect |
| Nov 6, 2025 | Weiss AmirChief Accounting Officer · O | ▼ Sale | 12,300 | $24.44 | $301K | -40.7% | — |
| Sep 5, 2025 | McAvoy David R.EVP, Chief Legal Officer · O | ▲ Buy | 1,113 | $18.86 | $21K | +9.3% | — |
Every $TEVA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Teva Pharmaceutical Industries filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TEVA feed.